Syngle Therapeutics is dedicated to developing an innovative immunotherapy aimed at treating Parkinson's disease, focusing on the specific targeting of oligomeric forms of alpha-synuclein. This protein is a key component of Lewy bodies, which are characteristic of Parkinson's pathology. The company has developed proprietary antibodies that selectively bind to these toxic oligomers, which are believed to play a significant role in the disease's progression. By targeting these aggregates, Syngle aims to create a treatment that not only alleviates symptoms but also modifies the disease's course, potentially offering a long-term solution for the millions affected by Parkinson's.

In addition to its antibody development, Syngle Therapeutics is exploring a gene therapy approach to enhance the delivery of these antibodies directly to the brain. This method aims to overcome the challenge of antibodies' limited ability to cross the blood-brain barrier, allowing for a one-time administration that could provide sustained therapeutic effects. The company has received financial support from The Michael J. Fox Foundation for its research and has filed a patent application for its most promising antibody, 26F1. Through these advanced technologies, Syngle Therapeutics is positioning itself at the forefront of innovative treatments for Parkinson's disease and related synucleinopathies.

Netherlands

Syngle Therapeutics is focused on developing an immunotherapy for the treatment of Parkinson’s disease. Syngle possesses several antibodies against oligomeric alphasynuclein, the main toxic species in Parkinson pathology.

Syngle Therapeutics

Company Details